Cytokines and the hepatic acute-phase response

Seminars in Liver Disease

Volumn 19, Issue 2, 1999, Pages 141-156

  Ramadori, G ^a   Christ, B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Acute phase response; Cytokines; Inflammation; Liver

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; LIVER ENZYME; PLASMA PROTEIN;

ACUTE PHASE RESPONSE; HEPATITIS; LIVER CELL; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 0032771993     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007106     Document Type: Review

References (173)

1. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982;289:39-48
2. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80
3. Sipe J, Ramadori G. Sites of SAA/AA synthesis. In: Marrink J, Van Rijswijk MH, eds. Amyloidosis. Dordrecht: Martinus Nijhoff, 1986:319-327
4. Ramadori G, Sipe JD, Colten HR. Expression and regulation of the murine serum amyloid A (SAA) gene in extrahepatic sites. J Immunol 1985;135:3645-3647
5. Fey GH, Fuller GM. Regulation of acute phase gene expression by inflammatory mediators. Mol Biol Med 1987;4:323-338
6. Fey GH, Gauldie J. The acute phase response of the liver in inflammation. Prog Liver Dis 1990;9:89-116
7. Koj A. Definition and classification of acute phase proteins. In: Gordon AH, Koj A, eds. The Acute Phase Response to Injury and Infection. Amsterdam: Elsevier, 1985:139-144
8. Koj A. Acute phase reactants - Their synthesis, turnover and biological significance. In: Allison AC, ed. Structure and Function of Plasma Proteins. Vol 1. New York: Plenum, 1997: 73-131
9. Ramadori G, Sipe JD, Dinarello CA, et al. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin-1 (IL-1) and purified human IL-1. J Exp Med 1985;162:930-942
10. Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-7255
11. Andus T, Geiger T, Hirano T, et al. Action of recombinant human interleukin 6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute-phase proteins. Eur J Immunol 1988;18:739-746
12. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-239
13. Ramadori G, Van Damme J, Rieder H, Meyer zum Büschenfelde KH. Interleukin 6 the third mediator of acute phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1β and tumor necrosis factor α. Eur J Immunol 1988;8:1259-1264
14. Mortensen RF, Shapiro J, Lin BF, et al. Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins. J Immunol 1988;140:2260-2266
15. Ramadori G, Meyer zum Büschenfelde KH. Liver cells and cytokines. Curr Opin Gastroenterol 1993;9:359-366
16. Dimitris A, Papanicolau, Wilder RL, et al. The pathophysiologic roles of interleukin-6 in human diseases. Ann Intern Med 1998;128:127-137
17. Püschel G, Jungermann K. Integration of function in the hepatic acinus: Intercellular communication in neural and humoral control of liver metabolism. Prog Liv Dis 1994;12:19-46
18. Feder LS, Todaro JA, Laskin DL. Characterization of interleukin-1 and interleukin-6 production by hepatic endothelial cells and macrophages. J Leukoc Biol 1993;53:126-132
19. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 1990;11:367-373
20. Clemens MG, Bauer M, Gingalewski C, et al. Hepatic intercellular communication in shock and inflammation. Shock 1994;2:1-9
21. Saad B, Frei K, Scholl FA, et al. Hepatocyte-derived interleukin-6 and tumor-necrosis factor alpha mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes. Eur J Biochem 1995;229:349-355
22. Rowell DL, Eckmann L, Dwinell MB, et al. Human hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial invasion. Am J Physiol 1997;273:G322-G332
23. Gressner AM. Hepatic fibrogenesis: The puzzle of interacting cells, fibrogenic cytokines, regulatory loops, and extracellular matrix molecules. Z Gastroenterol 1992;30:5-16
24. Schwögler S, Odenthal M, Meyer-zum-Buschenfelde KH, Ramadori G. Alternative splicing products of the tenascin gene distinguish rat liver fat storing cells from arterial smooth muscle cells and skin fibroblasts. Biochem Biophys Res Commun 1992;185:768-775
25. Desmouliere A, Tuchweber B, Gabbiani G. Role of the myofibroblast differentiation during liver fibrosis. J Hepatol 1995; 22:61-64
26. Armbrust T, Batusic D, Ringe B, Ramadori G. Mast cells distribution in human liver disease and experimental rat liver fibrosis. Indications for mast cell participation in development of liver fibrosis. J Hepatol 1997;26:1042-1054
27. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997;29:43-54
28. 4-treated rats by the weekly induction of acute phase response episodes: Upregulation of α1(I) procollagen and tissue inhibitor of metalloproteinase-1 mRNAs. Biochim Biophys Acta 1997;1361:177-184
29. Jungermann K. Zonation of metabolism and gene expression in liver. Histochem Cell Biol 1995;103:81-91
30. Jungermann K, Kietzmann T. Zonation of parenchymal and non-parenchymal metabolism in liver. Annu Rev Nutr 1996;16: 179-203
31. Feldmann G, Scoazec JY, Racine L, Bernuau D. Functional hepatocellular heterogeneity for the production of plasma proteins. Enzyme 1992;46:139-154
32. Burt AD, Le Bail B, Balabaud C, Bioulac-Sage P. Morphologic investigation of sinusoidal cells. Semin Liver Dis 1993;13: 21-38
33. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636
34. Knolle P, Löhr H, Treichel U, et al. Parenchymal and non-parenchymal liver cells and their interaction in the local immune response. Z Gastroenterol 1995;33:613-620
35. Wilson PC, Manj M, Neoptolemos J. Acute pancreatitis as a model of sepsis. J Antimicrob Chemother 1998;41:51-63
36. Waage A, Brandtzaeg P, Halstensen A, et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989;169:333-338
37. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin 6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996;224:647-664
38. Armbrust T, Schmitt E, Ramadori G. Viable rat Kupffer cells synthesize but not secrete Interleukin-1 - Indications for necrosis-induced maturation of Interleukin-1α, but not of Interleukin-1β. Biochem Biophys Res Commun 1995;207:637-645
39. Perregaux D, Gabel ChA. Interleukin 1β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994;269:15195-15203
40. Perregaux DG, Gabel ChA. Post-translational processing of murine IL-1: Evidence that ATP-induced release of IL-1α and IL-1β occurs via a similar mechanism. J Immunol 1998;160: 2469-2477
41. Dinarello CA. Induction of interleukin-1 and interleukin-1 receptor antagonist. Semin Oncol 1997;24:S9-81-S9-93
42. Argiles JM, Lopez-Soriano J, Busquets S, Lopez-Soriano FJ. Journey from cachexia to obesity by TNF. FASEB J 1997;11:743-751
43. Baumann H, Ziegler SF, Mosley B, et al. Reconstitution of the response to leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in hepatoma cells. J Biol Chcm 1993;268: 8414-8417
44. Kishimoto T, Akira S, Narazaki M, Taga-T. Interleukin-6 family of cytokines and gp110. Blood 1995;86:1243-1254
45. Hibi M, Nukujima K, Hirano T. IL-6 cytokine family and signal transduction: A model of the cytokine system. J Mol Med 1996;74:1-12
46. Campos SP, Wang Y, Koj A, Baumann H. Divergent transforming growth factor-beta effects on IL-6 regulation of acute phase plasma proteins in rat hepatoma cells. J Immunol 1993;151: 7128-7137
47. Kordula T, Guttgemann I, Rose-John S, et al. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). Up-regulation by interleukin-6 and transforming growth factor beta 1. FEBS Lett 1992;313:143-147
48. Guillen MI, Gomez-Lechon MJ, Nakamura T, Castell JV. The hepatocyle growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: Divergent effect on interleukin-6-stimulated genes. Hepatology 1996;23:1345-1352
49. Schaper F, Siewert E, Gomez-Lechon MJ, et al. Hepatocyte growth factor/scatter factor (HGF/SF) signals via the STAT3/ APRF transcription factor in human hepatoma cells and hepatocytes. FEBS Lett 1997;405:99-103
50. Wang Y, Kuropatwinski KK, White DW, et al. Leptin receptor action in hepatic cells. J Biol Chem 1997;272:16216-16223
51. Birch HE, Schreiber G. Transcriptional regulation of plasma protein synthesis during inflammation. J Biol Chem 1986;261: 8077-8080
52. Goldberger G, Bing DH, Sipe JD, et al. Transcriptional regulation of genes encoding the acute-phase proteins CRP, SAA, and C3. J Immunol 1987;138:3967-3971
53. Andus T, Geiger T, Hirano T, et al. Action of recombinant human interleukin 6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute-phase proteins. Eur J Immunol 1988;18:739-746
54. Morronc G, Ciliberto G, Oliviero S, et al. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 1988;263:12554-12558
55. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997;181:257-266
56. Ramadori G, Meyer zum Büschenfelde KH, Tobias PS, et al. Biosynthesis of lipopolysaccharide-binding protein in rabbit hepatocyies. Pathobiology 1990;58:89-94
57. Ihara S, Takahashi A, Hatsuse H, et al. Major component of RA-reactive factor, a complement activating bactericidal protein in mouse serum. J Immunol 1991;146:1874-1879
58. Knittel Th, Fellmer P, Neubauer K, et al. The complement-activating protease P100 is expressed by hepatocytes and is induced by IL-6 in vitro and during the acute phase reaction in vivo. Lab Invest 1997;77:221-230
59. Sevaljevic L, Ivanovic MS, Petrovic M, et al. Regulation of plasma acute-phase protein and albumin levels in the liver of scalded rats. Biochem J 1989;258:663-668
60. Milland J, Tsykin A, Thomas T, et al. Gene expression in regenerating and acute-phase rat liver. Am J Physiol 1990;259: G340-G347
61. Citarella F, Felici A, Brouwer M, et al. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood 1997;90:1501-1507
62. Morrone G, Cortese R, Sorrentino V. Post-transcriptional control of negative acute phase genes by transforming growth factor beta. EMBO J 1989;8:3767-3771
63. Feingold KR, Pollock AS, Moser AH, et al. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res 1995;36:1474-1482
64. Sewer MB, Koop DR, Morgan ET. Endotoxemia in rats is associated with induction of the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug Metab Dispos 1996;24:401-407
65. Morgan ET, Thomas KB, Swanson R, et al. Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochim Biophys Acta 1994;1219:475-483
66. Maheo K, Antras-Ferry J, Morel F, et al. Modulation of glutathione S-transferase subunits A2, M1, and P1 expression by interleukin-1beta in rat hepatocytes in primary culture. J Biol Chem 1997;272:16125-16132
67. Hill M, McCallum R. Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. J Clin Invest 1991;88:811-816
68. Hill MR, McCallum RE. Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice. Infect Immun 1992;60:4040-4050
69. Christ B, Nath A, Heinrich PC, Jungermann K. Inhibition by recombinant human interleukin-6 of the glucagon-dependent induction of phosphoenolpyruvate carboxykinase and of the insulin-dependent induction of glucokinase gene expression in cultured rat hepatocytes: Regulation of gene transcription and messenger RNA degradation. Hepatology 1994;20:1577-1583
70. Christ B, Nath A, Jungermann K. Mechanism of the impairment of the glucagon-stimulated phosphoenolpyruvate carboxykinase gene expression by interleukin-6 in cultured rat hepatocytes: Inhibition of the increase in cyclic 3′,5′ adenosine monophosphate and the downstream cyclic 3′,5′ adenosine monophosphate action. Hepatology 1997;26:73-80
71. Christ B, Nath A. Impairment by interleukin 1 beta and tumour necrosis factor alpha of the glucagon-induced increase in phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis in cultured rat hepatocytes [published erratum appears in Biochem J 1997;321:903]. Biochem J 1996;320:161-166
72. Klasing KC. Nutritional aspects of leukocytic cytokines. J Nutr 1988;118:1436-1446
73. Andus T, Bauer G, Gerok W. Effects of cytokines on the liver. Hepatology 1991;13:364-375
74. Andus T, Palitzsch KD, Gross V, Schölmerich J, The metabolic and endocrine functions of the cytokines. Dtsch Med Wochenschr 1993;188:306-313
75. Schreiber G. Synthesis, processing and secretion of plasma proteins by the liver and other organs and their regulation. In: The Plasma Proteins. Putnam FW, ed. Vol. 5. San Diego: Academic Press, 1987;5:293-363
76. Filkins JP. Monokines and the metabolic pathophysiology of septic shock. Fed Proc 1985;44:300-304
77. Memon RA, Feingold KR, Grunfeld C. The effect of cytokines on intermediary metabolism. Endocrinologist 1994;4:56-63
78. Mizock BA. Alterations in carbohydrate metabolism during stress: A review of the literature. Am J Med 1995;98:75-84
79. Fantuzzi G, Dinarello CA. The inflammatory response in interleukin-1 beta-deficient mice: Comparison with other cytokine-related knock-out mice. J Leukoc Biol 1996;59:489-493
80. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-342
81. Libert C, Takahashi N, Cauwels A, et al. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol 1994;24:2237-2242
82. Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994;180: 1243-1250
83. Taniguchi T, Takata M, Ikeda A, et al. Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor alpha-deficient mice. Lab Invest 1997;77:647-658
84. Fantuzzi Giamilia GKu, Harding MW, Livingston DJ, et al. Response to local inflammation of IL-1β-converting enzyme-deficient mice. J Immunol 1997;158:1818-1824
85. Lip AH, Banerjee S, Franklin S, et al. Mice devident in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 1995;80:401
86. Glaccum MB, Stocking KL, Charrier K, et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 1997;159:3364-3371
87. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-952
88. Labow M, Shuster D, Zetterstrom M, et al. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 1997;159:2452-2461
89. Leon LR, Kozak W, Peschon J, Kluger MJ. Exacerbated febrile responses to LPS, but not turpentine, in TNF double receptor-knockout mice. Am J Physiol 1997;272:R563-R569
90. Akira S, Yoshida K, Tanaka T, et al. Targeted disruption of the IL6 related genes: gp130 and NF-IL6. Immunol Rev 1995; 148:221-235
91. Yoshida K, Taga T, Saito M, et al. Targeted disruption of gp130, a common signal transducer for the IL6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996;93:407-411
92. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 1994;300:281-290
93. Peters M, Jacobs S, Ehlers M, et al. The function of the soluble interleukin 6 ( IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996;183: 1399-1406
94. Peters M, Schirmacher P, Goldschmitt J, et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med 1997;185:755-766
95. Peters M, Meyer-zum-Buschenfelde KH, Rose-John S. The function of the soluble IL-6 receptor in vivo. Immunol Lett 1996;54:177-184
96. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein [see comments]. Science 1990;249:1431-1433
97. Su GL, Simmons RL, Wang SC. Lipopolysaccharide binding protein participation in cellular activation by LPS. Crit Rev Immunol 1995;15:201-214
98. Wurfel MM, Monks BG, Ingalls RR, et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med 1997;186:2051-2056
99. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997;389:742-745
100. Perera PY, Vogel SN, Detore GR, et al. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J Immunol 1997;158:4422-4429
101. Haziot A, Lin XY, Zhang F, Goyert SM. The induction of acute phase proteins by lipopolysaccharide uses a novel pathway that is CD14-independent. J Immunol 1998;160:2570-2572
102. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988;241:825-828
103. Davis S, Aldrich TH, Valenzuela DM, et al. The receptor for ciliary neurotrophic factor. Science 1991;253:59-63
104. Hilton DJ, Hilton AA, Raicevic A, et al. Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J 1994;13: 4765-4775
105. Aikawa J, Ikeda-Naiki S, Ohgane J, Min KS, et al. Molecular cloning of rat leukemia inhibitory factor receptor alpha-chain gene and its expression during pregnancy. Biochim Biophys Acta 1997;1353:266-276
106. Gearing DP, Comeau MR, Friend DJ, et al. The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science 1992;255:1434-1437
107. Mosley B, De Imus C, Friend D, et al. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996;271:32635-32643
108. Sporeno E, Paonessa G, Salvati AL, et al. Delmastro P, Ciliberto G, Toniatti C, Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors. J Biol Chem 1994;269:10991-10995
109. Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994;19:222-227
110. Taga T, Kishimoto T. Signaling mechanisms through cytokinc receptors that share signal transducing receptor components. Curr Opin Immunol 1995;7:17-23
111. Hibi M, Nakajima K, Hirano T. IL-6 cytokine family and signal transduction: A model for the cytokine system. J Mol Med 1996;74:1-12
112. Heim MH, Kerr IM, Stark GR, Darnell JE Jr. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995;267:1347-1349
113. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391:285-288
114. Gronowski AM, Zhong Z, Wen Z, et al. In vivo growth hormone treatment rapidly stimulates the tyrosine phosphorylation and activation of Stat3. Mol Endocrinol 1995;9:171-177
115. Campbell GS, Meyer DJ, Raz R, et al. Activation of acute phase-response factor (APRF)/Stat3 transcription factor by growth hormone. J Biol Chem 1995;270:3974-3979
116. Wang Y, Morella KK, Ripperger J, et al. Receptors for interleukin-3 (IL-3) and growth hormone mediate an IL-6-type transcriptional induction in the presence of JAK2 or STAT3. Blood 1995;86:1671-1679
117. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997;272:32686-32695
118. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE, et al. Direct effects of leptin on brown and white adipose tissue. J Clin Invest 1997;100:2858-2864
119. Thanos T, Maniatis T. NF-κB: A lesson in family values. Cell 1995;80:529-532
120. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994;77: 325-328
121. Schülze S, Machleidt T, Krönke M. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 1994;56:533-541
122. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-1725
123. Baker SJ, Premkumar Reddy E. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 1996;12:1-9
124. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996;84:299-308
125. Wilmore DW, Lindsay CA, Moylan JA, et al. Hyperglucagonaemia after burns. Lancet 1974;1:73-75
126. Black PR, Brooks DC, Bessey PQ, et al. Mechanisms of insulin resistance following injury. Ann Surg 1982;196:420-435
127. Thorell A, Loftenius A, Andersson B, Ljungqvist O. Postoperative insulin resistance and circulating concentrations of stress hormones and cytokines. Clin Nutr 1996;15:75-79
128. Hack CE, DeGroot ER, Felt-Bersma-RJ, et al. Increased plasma IL-6 levels in sepsis. Blood 1989;74:1704-1710
129. Leser HG, Gross V, Scheibenhogen C, et al. Elevation of serum interleukin-6 concentration precedes acute phase response and reflects severity in acute pancrealitis. Gastroenterology 1991; 101:782-785
130. Ceppi ED, Tithergrade MA. The importance of nitric oxide in the cytokine-induced inhibition of glucose formation by cultured rat hepatocytes incubated with insulin, dexamethasone, and glucagon. Arch Biochem Biophys 1998;349:167-174
131. Bycrley LO, Alcock NW, Starnes HFJ. Sepsis-induced cascade of cytokine mRNA expression: Correlation with metabolic changes. Am J Physiol 1992;262:E728-E735
132. Saltiel AR. The paradoxical regulation of protein phosphorylation in insulin action. FASEB J 1994;8:1034-1040
133. White MF, Kahn R. The insulin signaling system. J Biol Chem 1994;269:1-4
134. Myers MG Jr, Jian Sun X, White MF. The IRS-1 signaling system. Trends Biol Sci 1994;19:289-293
135. Uddiri S, Yenush L, Sun XJ, et al. Interferon-α engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. J Biol Chem 1995;270:15938-15941
136. Yenush L, White MF. The IRS-signalling system during insulin and cytokine action. BioEssays 1997;19:491-500
137. Kanety H, Feinstein R, Papa MZ, et al. Tumor necrosis factor α-induced phosphorylalion of insulin receptor substrate-1 (IRS-1). J Biol Chem 1995;270:23780-23784
138. Argetsinger LS, Hsu GW, Myers MG Jr, et al. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J Biol Chem 1995;270:14685-14692
139. Platanias LC, Uddin S, Yetter A, et al. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. J Biol Chem 1996;271:278-282
140. Guo D, Donner DB. Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem 1996;271:615-618
141. Peraldi P, Hotamisligil GS, Buurman WA, et al. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996;271:13018-13022
142. OÔRiordain MG, Ross JA, Fearon KCH, et al. Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol 1995;269:E323-E330
143. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 1992;12:1789-1797
144. Neumann C, Zehentmaier G, Danhauser-Riedl S, et al. Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein She, and its complex formation with Grb2 in the human multiple myeloma cell line LP-I. Eur J Immunol 1996;26:379-384
145. Boulton TG, Stahl N, Yancopoulos GD. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induce tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J Biol Chem 1994;269:11648-11655
146. Bertrand F, Philippe C, Antoine PJ, et al. Insulin activates nuclear factor KB in mammalian cells through a Raf-1 mediated pathway. J Biol Chem 1995;270:24435-24441
147. Dayer JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw 1994;5:563-571
148. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991;88:1445-1451
149. Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995;40:365-394
150. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227
151. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147
152. Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 1991;174:1251-1254
153. Bertini R, Delgado R, Faggioni R, et al. Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock. Eur Cylokine Netw 1993;4:39-42
154. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-308
155. Olsson I, Gatanaga T, Gullberg U, et al. Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993;4:169-180
156. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-160
157. Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-118
158. Groeneveld PH, Kwappenberg KM, Langermans JA, et al. Relation between pro-and anti-inflammatory cytokines and the production of nitric oxide (NO) in severe sepsis. Cytokine 1997; 9:138-142
159. Van Dissel JT, Van Langevelde P, Westendorp RGJ, et al. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-953
160. Loyer P, Ilyin G, Abdel-Razzak Z, et al. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 1993;336:215-220
161. Xing Z, Gauldie J, Cox O, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-320
162. Mizuhara H, O'Neill E, Seki N, et al. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994;179:1529-1537
163. Jordan M, Otterness IG, Ng R, et al. Neutralization of endogenous IL-6 suppresses induction of IL-1 receptor antagonist. J Immunol 1995;154:4081-4090
164. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18:428-432
165. Fantuzzi G, Di-Santo E, Sacco S, et al. Role of the hypothalamus-pituitary-adrenal axis in the regulation of TNF production in mice. Effect of stress and inhibition of endogenous glucocorticoids. J Immunol 1995;155:3552-3555
166. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation [see comments]. N Engl J Med 1995;332:1351-1362
167. Hawes AS, Rock CS, Keogh CV, et al. In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect Immun 1992;60: 2641-2647
168. Zuckerman SH, Shellhaas J, Butler LD. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: Effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 1989;19:301-305
169. Parant M, Le-Contel C, Parant F, Chedid L. Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res 1991;10: 265-271
170. Wilckens Th, De Rijk R. Glucocorticoids and immune function: Unknown dimensions and new frontiers. Immunol Today 1997; 18:418-424
171. Koj A. Termination of acute phase response: A role of some cytokines and antiinflammatory drugs. Gen Pharmacol 1998;31: 9-18
172. Jack RS, Fan X, Bernheidem M, et al. Lipopolysaccharide binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997;389:742-745
173. Lamping N, Dettmer R, Schröder NWJ, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998;101:2065-2071